Article
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
The lancet. HIV - 1 Aug 2015
Rockstroh Jürgen K, Nelson Mark, Katlama Christine, Lalezari Jay, Mallolas Josep, Bloch Mark, Matthews Gail V, Saag Michael S, Zamor Philippe J, Orkin Chloe, Gress Jacqueline, Klopfer Stephanie, Shaughnessy Melissa, Wahl Janice, Nguyen Bach-Yen T, Barr Eliav, Platt Heather L, Robertson Michael N, Sulkowski Mark
Abstract excerpt
BACKGROUND: Hepatitis C virus (HCV) infection is a leading cause of morbidity and mortality in patients with HIV-1. The C-EDGE CO-INFECTION study assessed the efficacy, safety, and tolerability of grazoprevir (MK-5172) plus elbasvir (MK-8742) in patients with HCV and HIV co-infection. METHODS: In this uncontrolled, non-randomised, phase 3, open-label, single-arm study, treatment-naive patients with chronic HCV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.